Although we observed variation in baseline killing by T cells across donors, the phenotype observed following treatment with SHP2 inhibitors was reproducible (Fig. 1b,e) and consistent across a panel of cancer cell lines (Supplementary Fig. 2a–d). The gene discussed is PTPN11; the disease is cancer.